A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given Concomitantly With REPEVAX in Preadolescents and Adolescents (11 to 15 Year Olds)

Trial Profile

A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given Concomitantly With REPEVAX in Preadolescents and Adolescents (11 to 15 Year Olds)

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant nonavalent Merck (Primary) ; DTaP poliovirus vaccine
  • Indications Cervical cancer; Diphtheria; Human papillomavirus infections; Pertussis; Poliomyelitis; Tetanus; Vulvovaginal cancer
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Merck & Co
  • Most Recent Events

    • 24 Jun 2011 Status changed from active, no longer recruiting to completed.
    • 19 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 15 Oct 2010 Additional locations identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top